MAML1: Mastermind-Like Transcriptional Coactivator 1 (G9794)

Target Name: MAML1

NCBI ID: G9794

MAML1

MAML1: Mastermind-Like Transcriptional Coactivator 1

MAML1, or Mastermind-Like Transcriptional Coactivator 1, is a non-coding RNA molecule that plays a critical role in the regulation of gene expression in various organisms, including humans. MAML1 is a protein that can interact with the transcription factors, which are responsible for bringing specific DNA sequences to the attention of the RNA polymerase for transcription.

MAML1 is a 21-kDa protein that consists of 155 amino acid residues. It has a unique structure that includes a nucleotide-binding oligomerization domain (NBO), a domain that can interact with DNA-bound transcription factors, as well as a hypervariable region (HVR) that is responsible for the diversity of MAML1 expression.

MAML1 has been shown to play a role in the regulation of various cellular processes, including cell growth, differentiation, and apoptosis. For example, MAML1 has been shown to be involved in the regulation of cell cycle progression, where it can either promote or inhibit the G1/S transition. Additionally, MAML1 has been shown to play a role in the regulation of angiogenesis, where it can either promote or inhibit the formation of blood vessels.

MAML1 has also been shown to be involved in the regulation of inflammation. For example, MAML1 has been shown to play a role in the regulation of the production of pro-inflammatory cytokines, such as TNF-伪 and IL-1尾. Additionally, MAML1 has been shown to play a role in the regulation of the immune response, where it can either enhance or dampen the activity of the immune system.

MAML1 has also been shown to play a role in the regulation of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. For example, MAML1 has been shown to play a role in the regulation of the production of neurotoxins, which are harmful substances that can cause neurodegeneration. Additionally, MAML1 has been shown to play a role in the regulation of the immune response, where it can either enhance or dampen the activity of the immune system in the brain.

Despite its involvement in a wide range of cellular processes, MAML1 is not well understood, and there is a lack of research on its biology and function. As a result, MAML1 is an attractive drug target for researchers to study, as it has the potential to be a new therapeutic agent for a variety of diseases.

In conclusion, MAML1 is a non-coding RNA molecule that plays a critical role in the regulation of gene expression in various organisms. Its unique structure and diverse functions make it an attractive drug target for researchers to study, and further research is needed to fully understand its biology and potential therapeutic uses.

Protein Name: Mastermind Like Transcriptional Coactivator 1

Functions: Acts as a transcriptional coactivator for NOTCH proteins. Has been shown to amplify NOTCH-induced transcription of HES1. Enhances phosphorylation and proteolytic turnover of the NOTCH intracellular domain in the nucleus through interaction with CDK8. Binds to CREBBP/CBP which promotes nucleosome acetylation at NOTCH enhancers and activates transcription. Induces phosphorylation and localization of CREBBP to nuclear foci. Plays a role in hematopoietic development by regulating NOTCH-mediated lymphoid cell fate decisions

The "MAML1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAML1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets